Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARIFY MS 2-year follow-up cognition and quality of life study
2020-003874-30Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoint: No or minimal decline in cognitive function at year 4. Started Nov 2020; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-003874-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003874-30.